Anti-Hu CD38 PE-DyLight™ 594

*Leukocyte Typing III., McMichael AJ et al (Eds.), Oxford University Press (1987) ., URL: , *Rozková D, Novotná L, Pytlík R, Hochová I, Kozák T, Bartůnková J, Spísek R: Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer. 2010 Mar 1;126 (5) :1132-43., URL: https://www.ncbi.nlm.nih.gov/pubmed/19685493, *Kolar GR, Mehta D, Pelayo R, Capra JD: A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood. 2007 Mar 15;109 (6) :2545-52., URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852199/, *Všianská P, Říhová L, Varmužová T, Suská R, Kryukov F, Mikulášová A, Kupská R, Penka M, Pour L, Adam Z, Hájek R: Analysis of B-cell subpopulations in monoclonal gammopathies. Clin Lymphoma Myeloma Leuk. 2015 Apr;15 (4) :e61-71., URL: http://www.ncbi.nlm.nih.gov/pubmed/25578543 , *Ratuszny D, Skripuletz T, Wegner F, Groß M, Falk C, Jacobs R, Ruschulte H, Stangel M, Sühs KW: Case report: Daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis. Front Neurol. 2020 Dec 22;11:602102., URL: https://pubmed.ncbi.nlm.nih.gov/33414761/, *Pape LJ, Hambach J, Gebhardt AJ, Rissiek B, Stähler T, Tode N, Khan C, Weisel K, Adam G, Koch-Nolte F, Bannas P: CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy. Front Immunol. 2022 Oct 27:13:1010270., URL: https://pubmed.ncbi.nlm.nih.gov/36389758/, *Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D: Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008 Aug 1;112 (3) :568-75., URL: https://pubmed.ncbi.nlm.nih.gov/18523148/, *Ruiz-Lorente I, Gimeno L, López-Abad A, López Cubillana P, Fernández Aparicio T, Asensio Egea LJ, Moreno Avilés J, Doñate Iñiguez G, Guzmán Martínez-Valls PL, Server G, Ferri B, Campillo JA, Martínez-Sánchez MV, Minguela A: Differential role of NKG2A/HLA-E interaction in the outcomes of bladder cancer patients treated with M. bovis BCG or other therapies. Biomedicines 2025 Jan 10;13 (1) :156., URL: https://pubmed.ncbi.nlm.nih.gov/39857739/, *Kužílková D, Puñet-Ortiz J, Aui PM, Fernández J, Fišer K, Engel P, van Zelm MC, Kalina T: Standardization of workflow and flow cytometry panels for quantitative expression profiling of surface antigens on blood leukocyte subsets: An HCDM CDMaps initiative. Front Immunol. 2022 Feb 11:13:827898. , URL: https://pubmed.ncbi.nlm.nih.gov/35222411/

*Cakir-Kiefer C, Muller-Steffner H, Oppenheimer N, Schuber F: Kinetic competence of the cADP-ribose-CD38 complex as an intermediate in the CD38/NAD+ glycohydrolase-catalysed reactions: implication for CD38 signalling. Biochem J. 2001 Sep 1;358 (Pt 2) :399-406., URL: https://www.ncbi.nlm.nih.gov/pubmed/11513738?ordin, *Lund FE, Muller-Steffner H, Romero-Ramirez H, Moreno-García ME, Partida-Sánchez S, Makris M, Oppenheimer NJ, Santos-Argumedo L, Schuber F: CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl cyclase- and NAD glycohydrolase-independent mechanism. Int Immunol. 2006 Jul;18 (7) :1029-42., URL: https://www.ncbi.nlm.nih.gov/pubmed/16720618?ordin, *Partida-Sanchez S, Gasser A, Fliegert R, Siebrands CC, Dammermann W, Shi G, Mousseau BJ, Sumoza-Toledo A, Bhagat H, Walseth TF, Guse AH, Lund FE. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major product generated by the CD38 enzyme reaction. J Immunol. 2007 Dec 1;179 (11) :7827-39., URL: https://www.ncbi.nlm.nih.gov/pubmed/18025229?ordin

The mouse monoclonal antibody HIT2 reacts with an extracellular epitope of CD38, a 45 kDa type II transmembrane glycoprotein strongly expressed mainly on plasma cells and activated T and B lymphocytes; it is an antigenic marker of lymphoid cells. Its binding is blocked by daratumumab.